ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 255,01
0,58%
Dow Jones
44 296,51
0,97%
DAX
19 322,59
0,91%
Brent Oil
74,65
0,00%
Bitcoin
98 633,49
-0,40%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Aclaris Therapeutics Inc (ACRS)

  7. Aclaris Therapeutics Inc (ACRS) Actualités

ACRS

Aclaris Therapeutics (ACRS)

Aclaris Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ACRS
DateHeureSourceTitreSymboleSociété
22/11/202422h00Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ACRSAclaris Therapeutics Inc
20/11/202422h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
19/11/202422h05AllPennyStocks.comThis Healthcare Stock Soared Following Exclusive License Agreement AnnouncementNASDAQ:ACRSAclaris Therapeutics Inc
18/11/202422h20Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
18/11/202414h50PR Newswire (US)Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology AssetsNASDAQ:ACRSAclaris Therapeutics Inc
18/11/202414h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRSAclaris Therapeutics Inc
18/11/202414h10GlobeNewswire Inc.Aclaris Therapeutics Announces $80 Million Private PlacementNASDAQ:ACRSAclaris Therapeutics Inc
18/11/202414h10GlobeNewswire Inc.Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to PipelineNASDAQ:ACRSAclaris Therapeutics Inc
06/11/202422h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACRSAclaris Therapeutics Inc
06/11/202413h00GlobeNewswire Inc.Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
17/09/202413h00GlobeNewswire Inc.Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic DermatitisNASDAQ:ACRSAclaris Therapeutics Inc
10/09/202413h00GlobeNewswire Inc.Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare ConferenceNASDAQ:ACRSAclaris Therapeutics Inc
07/08/202413h00GlobeNewswire Inc.Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
16/07/202422h01GlobeNewswire Inc.Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 MillionNASDAQ:ACRSAclaris Therapeutics Inc
06/06/202413h00GlobeNewswire Inc.Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:ACRSAclaris Therapeutics Inc
07/05/202422h06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ACRSAclaris Therapeutics Inc
07/05/202422h01GlobeNewswire Inc.Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
30/04/202413h00GlobeNewswire Inc.Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
23/04/202414h00PR Newswire (US)Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive OfficerNASDAQ:ACRSAclaris Therapeutics Inc
27/02/202413h30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ACRSAclaris Therapeutics Inc
27/02/202413h00GlobeNewswire Inc.Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
15/02/202402h32Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ACRSAclaris Therapeutics Inc
05/02/202422h31Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ACRSAclaris Therapeutics Inc
16/01/202413h00GlobeNewswire Inc.Aclaris Therapeutics Announces Leadership Changes and Strategic Business ReviewNASDAQ:ACRSAclaris Therapeutics Inc
10/01/202413h00GlobeNewswire Inc.Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic DermatitisNASDAQ:ACRSAclaris Therapeutics Inc
19/12/202322h01GlobeNewswire Inc.Aclaris Therapeutics Provides Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
05/12/202322h01GlobeNewswire Inc.Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for AlopeciaNASDAQ:ACRSAclaris Therapeutics Inc
13/11/202313h00GlobeNewswire Inc.Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
06/11/202313h00GlobeNewswire Inc.Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
23/10/202322h06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ACRS

Dernières Valeurs Consultées

EU
BNP
BNP Paribas
NYSE
MCD
McDonalds
FTSE
UKX
FTSE 100
NASDAQ
GOOGL
Alphabet
NYSE
MRK
Merck
EU
DG
Vinci
EU
EN
Bouygues
EU
ACA
Credit Agricole
NASDAQ
AMZN
Amazon.com
EU
GLE
Societe Generale
EU
AI
Air Liquide
EU
RNO
Renault
COIN
XRPUSD
Ripple
EU
VIV
Vivendi
COIN
ADAUSD
Cardano
EU
PX1
CAC 40
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés

Vendredi fou

ADVFN

Célébrons nos 25 ans Est 1999-2024

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres
EU Flag

Cours Euronext en temps réel et illimités sur le site. Carnet d'ordres Euronext en direct